These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Price type key:
Federal Supply Schedule (FSS): generally available to all Federal Govt agencies /
'BIG4' prices: VA, DoD, Public Health & Coast Guard only /
National Contracts (NC): Available to specific agencies
67877-0576 Market Analysis and Financial Projection
The drug with NDC 67877-0576, identified as Minocycline Hydrochloride by Ascend Laboratories, LLC, is a generic antibiotic used to treat bacterial infections. Based on the provided search results and broader pharmaceutical market trends, here's an analysis of its market dynamics and price projections:
Market Analysis
Generic Drug Landscape
As a generic antibiotic, Minocycline Hydrochloride operates in a competitive market where price erosion is common. Generic drugs typically face annual price declines of 3–5% due to market saturation and competition[3].
Despite price erosion, revenue growth can still occur through volume expansion and market penetration[3][6].
Therapeutic Demand
Antibiotics like minocycline maintain steady demand due to persistent bacterial infections. However, pricing pressures are heightened by:
Generic competition: Multiple manufacturers producing similar formulations[3][10].
Regulatory policies: Efforts to reduce drug costs, such as Colorado’s Prescription Drug Affordability Review Board (PDAB), which may impose upper payment limits[7].
Manufacturer Profile
Ascend Laboratories specializes in generics (e.g., Sirolimus, Triamcinolone)[5][9], suggesting competitive pricing strategies. Their products often align with broader trends in the $33.51B U.S. ophthalmic market (growing at 7.6% CAGR)[2] and $634.4B global biologics market[6], though minocycline is not a biologic.
While specific sales data for NDC 67877-0576 is unavailable, analogous generics like Morphine Sulfate (NDC 67877-0670) show fluctuating prices but consistent market presence[3]. For example:
Morphine Sulfate prices ranged from $0.18 to $0.26 per unit between 2024 and 2025[3], reflecting competitive volatility.
Key Takeaways
Price Trends: Expect gradual declines (3–5% annually) unless market consolidation or regulatory interventions alter the trajectory.
Revenue Potential: Linked to prescription volume and geographic distribution efficiency.
Competitive Risks: New entrants or biosimilar launches (as seen in the adalimumab market)[4] could intensify pricing pressures.
For actionable insights, tracking state-specific affordability boards (e.g., Colorado PDAB)[7] and competitor filings (e.g., FDA’s ANDA database)[8] is critical.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
